1. Home
  2. PAX vs NUVB Comparison

PAX vs NUVB Comparison

Compare PAX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Patria Investments Limited

PAX

Patria Investments Limited

HOLD

Current Price

$11.27

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.28

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAX
NUVB
Founded
1988
2018
Country
Cayman Islands
United States
Employees
N/A
291
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.6B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PAX
NUVB
Price
$11.27
$4.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$20.00
$11.38
AVG Volume (30 Days)
896.3K
4.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.00
$182.76
Revenue Next Year
$15.87
$91.83
P/E Ratio
$25.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.44
$1.57
52 Week High
$17.80
$9.75

Technical Indicators

Market Signals
Indicator
PAX
NUVB
Relative Strength Index (RSI) 21.97 32.94
Support Level $10.12 $4.04
Resistance Level $14.53 $5.73
Average True Range (ATR) 0.42 0.29
MACD -0.03 -0.02
Stochastic Oscillator 3.76 6.61

Price Performance

Historical Comparison
PAX
NUVB

About PAX Patria Investments Limited

Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: